Taven EZ10 mg+10 mg

Taven EZ combines a statin (atorvastatin) with a cholesterol absorption inhibitor (ezetimibe) and is used for the following indications:

Established / Guideline-Supported Uses

• As an adjunct to diet, for treatment of primary hyperlipidemia (heterozygous familial and non-familial) or mixed dyslipidemia, to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B, triglycerides, and non-HDL-cholesterol, in patients whose response to statin monotherapy is inadequate, or who are already being treated with both agents.
• To reduce the risk of major cardiovascular events (myocardial infarction, stroke, revascularization) in patients with established atherosclerotic cardiovascular disease or at high cardiovascular risk, as part of an overall lipid-lowering strategy.

Adjunct / Combination-Only Use

• As adjunctive therapy to other lipid-lowering treatments (e.g. LDL apheresis) in homozygous familial hypercholesterolemia, when a greater degree of LDL-cholesterol reduction is needed than diet and a statin alone provide.

Taven EZ is not indicated for patients whose predominant abnormality is elevated chylomicrons (elevated triglycerides only, e.g. Fredrickson Type I, III, IV, and V dyslipidemia).

Atorvastatin + Ezetimibe is a fixed-dose combination oral tablet containing two active ingredients:

• Atorvastatin (as atorvastatin calcium) – an HMG-CoA reductase inhibitor (statin).
• Ezetimibe – a selective cholesterol absorption inhibitor.

It is commonly available in combined strengths such as atorvastatin 10 mg/20 mg/40 mg with ezetimibe 10 mg, though exact available strengths vary by manufacturer and market. Confirm the exact strength on the product pack before use.

Taven EZ is a fixed-dose combination medicine used to manage high cholesterol and mixed dyslipidemia. It works through two complementary mechanisms: atorvastatin lowers cholesterol production in the liver, while ezetimibe reduces the amount of cholesterol absorbed from the intestine. Together, they produce a greater reduction in LDL ("bad") cholesterol than either agent alone at comparable doses.

Taven EZ is intended for use alongside a cholesterol-lowering diet and other lifestyle measures, and is typically prescribed when treatment with a statin alone has not adequately controlled cholesterol levels, or when combination therapy is considered appropriate from the start based on a patient's cardiovascular risk.

Taven EZ belongs to the therapeutic class of antihyperlipidemic agents (lipid-lowering drugs), specifically a combination of an HMG-CoA reductase inhibitor (statin) and a cholesterol absorption inhibitor.

Atorvastatin + Ezetimibe lowers cholesterol through two distinct and complementary mechanisms:

Atorvastatin

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. By inhibiting this enzyme, atorvastatin reduces cholesterol production in the liver and increases the number of hepatic LDL receptors on the cell surface, which enhances uptake and clearance of LDL-cholesterol from the blood. It also reduces triglycerides and modestly raises HDL-cholesterol.

Ezetimibe

Ezetimibe acts at the brush border of the small intestine, where it selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein, blocking the absorption of dietary and biliary cholesterol. This reduces the amount of cholesterol delivered to the liver, which further upregulates hepatic LDL receptors and increases LDL-cholesterol clearance from the blood, complementing atorvastatin's effect.

Together, the two components of Atorvastatin + Ezetimibe act on both cholesterol synthesis and cholesterol absorption, producing an additive reduction in LDL-cholesterol.

Taven EZ should be taken by mouth, once daily, generally in the evening. It may be taken with or without food. Tablets should be swallowed whole with a glass of water; do not crush or chew unless specifically advised. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose, in which case the missed dose should be skipped — do not double the dose.

Taven EZ has several clinically significant drug interactions, mainly related to its atorvastatin component:

• Strong CYP3A4 inhibitors (e.g. clarithromycin, itraconazole, ketoconazole, certain HIV protease inhibitors, certain hepatitis C antivirals): increase atorvastatin blood levels, raising the risk of myopathy and rhabdomyolysis; some combinations require avoiding Taven EZ or limiting the atorvastatin dose.
• Cyclosporine: significantly increases atorvastatin exposure; concomitant use should generally be avoided.
• Gemfibrozil and other fibrates, and lipid-modifying doses of niacin: increase the risk of myopathy and rhabdomyolysis when combined with statins; use only if benefit clearly outweighs risk, with close monitoring.
• Grapefruit juice: large quantities (>1.2 L/day) can increase atorvastatin levels; avoid excessive consumption.
• Warfarin and other vitamin K antagonists: ezetimibe (and atorvastatin) may increase INR; monitor coagulation parameters closely when starting or stopping Taven EZ.
• Bile acid sequestrants (e.g. cholestyramine): reduce absorption of ezetimibe; Taven EZ should be taken at least 2 hours before or 4 hours after a bile acid sequestrant.
• Digoxin: atorvastatin may modestly increase digoxin levels; monitor as clinically appropriate.
• Oral contraceptives: atorvastatin may increase levels of ethinyl estradiol/norethindrone; consider when prescribing contraception.

Always inform the physician or pharmacist of all other medicines being taken before starting Taven EZ.

Most patients tolerate Taven EZ well; when side effects occur, they are usually mild. Reported side effects include:

Common

• Muscle aches/pain (myalgia)
• Diarrhea and other GI upset (more frequent with the ezetimibe component)
• Nasopharyngitis, joint pain (arthralgia)
• Elevated liver transaminases
• Headache

Less Common / Serious

• Myopathy, and rarely rhabdomyolysis (severe muscle breakdown with risk of kidney injury) — seek urgent medical attention for unexplained muscle pain, tenderness, or weakness, especially with fever or dark urine.
• Hepatotoxicity, including rare reports of liver failure.
• Hypersensitivity reactions, including rare angioedema.
• Rare reports of thrombocytopenia, pancreatitis, and gallstones/cholecystitis (associated with ezetimibe).

Taven EZ is contraindicated in pregnancy. The atorvastatin component can cause fetal harm; cholesterol and other products of cholesterol biosynthesis are essential for fetal development, and statin use during pregnancy has been associated with adverse outcomes in some reports. If pregnancy occurs while taking Taven EZ, it should be discontinued immediately and the physician informed. Taven EZ should only be given to women of childbearing potential who are highly unlikely to conceive and who have been informed of the potential risks.

Taven EZ is also contraindicated during breastfeeding, as statins may pass into breast milk and pose a risk of serious adverse effects in nursing infants. Women who require lipid-lowering therapy while breastfeeding should discuss alternative approaches with their physician.

The following precautions apply to Taven EZ:

Myopathy and Rhabdomyolysis

Taven EZ can cause myopathy, and rarely life-threatening rhabdomyolysis with acute kidney injury. Risk is increased with higher doses, advanced age, hypothyroidism, renal impairment, and concomitant use of interacting drugs (see Interactions). Patients should promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by fever or malaise.

Liver Enzyme Abnormalities

Persistent elevations in liver transaminases can occur. Liver function tests are recommended before starting therapy and if signs or symptoms of liver injury occur (fatigue, jaundice, dark urine, abdominal pain). Taven EZ should be discontinued if serious liver injury is suspected.

Diabetes Mellitus

Statins, including the atorvastatin component of Taven EZ, have been associated with modest increases in blood glucose and HbA1c, and increased risk of new-onset diabetes; the cardiovascular benefit generally outweighs this risk, but glycemic status should be monitored.

Renal and Hepatic Disease

Use with caution in patients with significant renal impairment, and avoid entirely in active liver disease (see Contraindications).

Alcohol Use

Patients who consume substantial quantities of alcohol should use Taven EZ with caution due to increased risk of liver problems.

There is limited specific experience with Taven EZ overdose. Based on its components, overdose may cause exaggerated side effects, potentially including significant GI upset and increased risk of myopathy/liver enzyme elevation. There is no specific antidote. In case of suspected overdose, seek immediate medical attention or contact a poison control center; treatment should be supportive, with monitoring of liver function and symptomatic management as directed by a physician. Do not attempt to manage an overdose at home without medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: No overall differences in safety or effectiveness of Taven EZ have been observed between elderly and younger patients, but elderly patients (especially those over 65) may have a higher risk of myopathy; use with appropriate monitoring.

Renal impairment: Generally no dose adjustment required for mild-to-moderate impairment; use with caution and medical supervision in significant renal disease.

Hepatic impairment: Contraindicated in active liver disease (see Contraindications); use with caution and monitoring in mild, stable hepatic impairment only if directed by a specialist.

Women of childbearing potential: Should use effective contraception during treatment; see Pregnancy and Lactation.

Pediatric patients: See Pediatric Uses.

Taven EZ is generally used long-term as part of ongoing management of chronic hypercholesterolemia and cardiovascular risk reduction, alongside continued lifestyle and dietary measures. Lipid levels are typically reassessed roughly 4–12 weeks after starting or adjusting therapy, with dose adjustments made as needed. Treatment duration should be determined by the prescribing physician based on ongoing cardiovascular risk and response to therapy; it is not intended for short-term or as-needed use.

HMG-CoA reductase inhibitor (statin) combined with a cholesterol absorption inhibitor (fixed-dose antihyperlipidemic combination).

Atorvastatin + Ezetimibe lowers LDL-cholesterol via two complementary actions: the atorvastatin component inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis and upregulating LDL receptors; the ezetimibe component blocks the NPC1L1 transporter in the intestinal brush border, reducing absorption of dietary and biliary cholesterol. The combined effect is a greater reduction in LDL-cholesterol than either mechanism alone.

X

The safety and effectiveness of Taven EZ as a fixed-dose combination have not been established in pediatric patients. Atorvastatin alone has established pediatric dosing for certain inherited lipid disorders in children above specific age thresholds (per local labeling), under specialist supervision, but the combination product Taven EZ is generally not recommended for use in children and adolescents unless specifically directed by a pediatric lipid specialist. Use in pediatric patients should only occur under close specialist supervision with regular monitoring of growth, development, and liver function.